Market Overview

Electromed, Inc. Announces Results of an Independent Clinical Study: Bronchiectasis Exacerbations Reduced, Lung Function Stabilized with SmartVest®

Share:

Electromed, Inc. (NYSE:ELMD) today announced the results of an
independent, outcome-based clinical study presented during the third
annual World Bronchiectasis Conference in Washington D.C. The study's
findings reveal that early use of high frequency chest wall oscillation
("HFCWO") therapy with the SmartVest® Airway Clearance System
significantly reduced severe exacerbations and hospitalizations among
non-cystic fibrosis bronchiectasis patients. The study is the first to
report "stabilization of key lung function parameters" as a result of
HFCWO use, suggesting early bronchiectasis treatment with HFCWO may
significantly slow the otherwise normal progression of the disease.

"We are thrilled not only by the results of this study, but the
significant milestone it represents," commented Kathleen Skarvan,
President and Chief Executive Officer of Electromed. "This is the first
independent study to evaluate bronchiectasis-related exacerbations using
HFCWO therapy. The results confirm what we've said all along:
incorporating the SmartVest into bronchiectasis treatment significantly
reduces exacerbations and improves patient outcomes."

Bronchiectasis is an irreversible, chronic lung condition characterized
by enlarged and permanently damaged bronchi. The condition is associated
with recurrent lower respiratory infections, inflammation, reduction in
pulmonary function, impaired respiratory secretion clearance, increased
hospitalizations and medication use, and increased morbidity and
mortality.1,2,3

"Preventing exacerbations and maintaining pulmonary function is vital to
the health and well-being of bronchiectasis patients," commented Chet
Sievert, Electromed's Director of Regulatory and Clinical Affairs. "This
independent study builds on previously published evidence and clearly
demonstrates that bronchiectasis patients can achieve significantly
better outcomes with the initiation of SmartVest therapy."

The SmartVest system uses HFCWO, a clinically proven therapy that helps
clear the lungs of excess secretions, thereby reducing the risk of
respiratory infections and hospitalizations. HFCWO delivers alternating
pulses of air into a vest garment that rapidly compresses and releases
the chest wall, resulting in an oscillation in airflow within the
airways that acts to loosen, thin, and propel mucus toward the major
airways where it can be expectorated.

About Electromed, Inc.

Electromed manufactures, markets, and sells products that provide airway
clearance therapy, including the SmartVest® Airway Clearance
System, to patients with compromised pulmonary function. It is
headquartered in New Prague, Minnesota and founded in 1992. Further
information about Electromed can be found at www.smartvest.com.
____________________________
1
King PT et al. COPD. 2005;2(1):27-34.
2
Alzeer AH et al. BMC Pulm Med. 2007; 7:17.
3
Seitz AE et al. Chest. 2010;138(4):944-949.

View Comments and Join the Discussion!